KR102611957B1 - Composition for preventing or treating muscular disease comprising syneilesis aconitifolia (bunge) maxim extract - Google Patents

Abstract

The present invention relates to a composition for the prevention or treatment of muscle disease containing an extract of Brachyphylla sinensis as an active ingredient. In more detail, it has the effect of increasing muscle mass by reducing the differentiation of osteoclasts related to muscle loss and promoting the formation of muscle fibers by including the extract of Achyranthes ginseng as an active ingredient. At the same time, there is no problem of side effects even if the dosage and period of use are increased. It relates to a composition for preventing or treating muscle diseases.

Description

Composition for preventing or treating muscle disease comprising extract of Achyranthes ginseng as an active ingredient {COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE COMPRISING SYNEILESIS ACONITIFOLIA (BUNGE) MAXIM EXTRACT}

The present invention relates to a composition for the prevention or treatment of muscle disease containing an extract of Brachyphylla sinensis as an active ingredient. In more detail, it has the effect of increasing muscle mass by reducing the differentiation of osteoclasts related to muscle loss and promoting the formation of muscle fibers by including the extract of Achyranthes ginseng as an active ingredient. At the same time, there is no problem of side effects even if the dosage and period of use are increased. It relates to a composition for preventing or treating muscle diseases.

Muscle is a tissue created by the development of mesoderm stem cells and is composed of bundles of muscle fibers (myofibers) made up of muscle cells (myoblasts). Muscles make up 40-50% of body weight, supporting and protecting bones and internal organs while enabling the movement of tissues other than muscles, such as heartbeat. In addition to protecting organs, muscles have a significant impact on nutrient metabolism as well as physical activity, including exercise, and are therefore closely related to the development of metabolic diseases such as diabetes, obesity, and cardiovascular disease.

A person's muscles decrease by more than 1% per year after the age of 40, and by the age of 80, 50% of maximum muscle mass is reduced, so muscle loss in old age is recognized as the most important factor in reducing overall physical function. Therefore, the need to improve muscle function is increasing, and the development of treatments for diseases related to muscle function decline is also becoming important.

The most important factor determining muscle function is muscle mass, which is maintained by the balance of protein synthesis and breakdown. Factors involved in muscle protein synthesis induce protein synthesis by phosphorylating downstream proteins starting from stimulation of the PI3K (phosphatidylinositol-3 kinase/Akt pathway) within muscle cells. mTOR (mammalian target) by PI3K/Akt signaling The activity of rapamycin is recognized as a central growth signaling factor that integrates various growth signals within the cell. Activation of mTOR involves two downstream targets, 4E-BP1 (4E-binding protein) and p70S6K (phosphorylated 70-). It contributes to an increase in muscle mass by inducing muscle protein synthesis by activating (kDa ribosomal S6 kinase). This increase in muscle protein synthesis appears as an increase in muscle size (hypertrophy) or an increase in the number of muscle fibers (hyperplasia) due to an increase in protein.

Conversely, when FoxO (forhead box), a transcription factor, moves from the cytoplasm into the nucleus, it increases the expression of atrogin-1 and MuRF-1, which are E3 ubiquitin ligase factors involved in protein degradation. , In this case, protein breakdown within the muscle is promoted, resulting in a decrease in muscle mass. In other words, protein decomposition occurs more than synthesis, causing muscle weakness and degeneration due to a decrease in muscle mass.

Therefore, promoting the activity of mTOR and suppressing the expression of atrogin-1 and MuRF-1 increases the amount of muscle protein and increases muscle mass, so mTOR, atrogin-1, MuRF- The expression of 1 is an important factor in regulating muscle mass.

Accordingly, there is a need to develop substances that can increase the expression of proteins related to muscle protein synthesis and muscle mass increase in muscle cells, and prevent and improve muscle weakness and degeneration by regulating muscle mass.

(Patent Document 1) KR 10-2017-0132705 A

The purpose of the present invention is to provide a composition for preventing or treating muscle disease containing an extract of Siberian ginseng.

Another object of the present invention is to provide a composition for preventing or treating muscle diseases derived from natural products that has the effect of increasing muscle mass by reducing differentiation of osteoclasts related to muscle loss and promoting muscle fiber formation.

Another object of the present invention is to provide a composition for preventing or treating muscle diseases that has no side effects and can be used periodically or over a long period of time.

In order to achieve the above object, a composition for preventing or treating muscle disease according to an embodiment of the present invention includes Syneilesis aconitifolia (Bunge) Maxim extract as an active ingredient.

The extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.

The muscle diseases include atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, amyotrophic lateral sclerosis, Charcot- It is characterized by at least one selected from the group consisting of Charcot-Marie-Tooth disease and sarcopenia.

The composition exhibits the ability to inhibit differentiation of osteoclasts.

The composition increases muscle mass through the effect of promoting muscle fiber formation.

A pharmaceutical composition according to another embodiment of the present invention includes the above composition.

A food composition according to another embodiment of the present invention includes the above composition.

Hereinafter, the present invention will be described in more detail.

The term “extract” used in this specification has the meaning commonly used in the art as a crude extract, as described above, but in a broad sense also includes fractions obtained by additional fractionation of the extract. In other words, extracts include not only those obtained using the above-mentioned extraction solvent, but also those obtained by additionally applying a purification process. For example, fractions obtained by passing the extract through an ultrafiltration membrane with a certain molecular weight cut-off value, separation by various chromatographs (designed for separation according to size, charge, hydrophobicity, or affinity), etc. Fractions obtained through purification methods are also included in the extract of the present invention.

As used herein, the term "comprising an active ingredient" refers to an amount sufficient to effect a desired biological effect, such as beneficial results, including but not limited to preventing, reducing, alleviating or eliminating signs or symptoms of a disease or disorder. It means that it contains, and this amount is called the “effective amount.” Accordingly, the total amount of each active ingredient in the composition or method is sufficient to produce significant individual benefit. Accordingly, the effective amount will vary depending on the circumstances in which it is administered.

Among the terms used in this specification, when a part "includes" a certain component, this means that it does not exclude other components but may further include other components unless specifically stated to the contrary. .

As used herein, the term “improvement” refers to any action that at least reduces the severity of a parameter, such as a symptom, associated with the alleviation or treatment of a condition.

The term “prophylaxis” herein refers to blocking the appearance of a disease or symptoms associated with a disease in an asymptomatic subject at risk of developing the disease, for example, by exposure to the cause of the disease.

The term “treatment” herein refers to a therapeutic intervention that improves the signs or symptoms of a disease or pathological condition after its onset.

A composition for preventing or treating muscle disease according to an embodiment of the present invention includes Syneilesis aconitifolia (Bunge) Maxim extract as an active ingredient.

Syneilesis aconitifolia (Bunge) Maxim is a perennial plant of the Asteraceae family with a height of 70-120 cm. The roots have short rhizomes that extend to the sides, and the main stem is purple and has no branches and has two leaves. The first leaf is round, 20-30cm in diameter, divided into long shapes, has 7-9 lobes, and is divided into two rows 2-3 times. The second leaf is slightly smaller, 12-24cm in diameter, the lobe is 4-5cm wide, and the petiole is 2-6cm long. The leaf is round, 20-30cm in diameter, divided into long shapes, and flowers bloom from July to August.

The brachyurysis extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.

Specifically, in order to produce an extract of the vegetable extract, the steps include washing the vegetable extract; Drying after washing; Grinding the baby umbrella greens after drying; leaching the pulverized material using an organic solvent; Leaching and drying the sample; Leaching using water; And, including the step of leaching, an extract of Aerobium chinensis can be obtained.

The extract extracted using the organic solvent may further include the step of performing fractionation using the organic solvent, and the method of preparing the extract may be a conventional extraction method in the art, such as ultrasonic extraction, leaching, and reflux extraction. You can.

Specifically, it may be an extract obtained by extracting a Papola shoot extract from which foreign substances have been removed by washing and drying with water, alcohol having 1 to 6 carbon atoms, or a mixed solvent thereof, and may be an extract obtained by sequentially applying the solvents to the sample.

The reflux extraction method is based on 100 mL of water and alcohol with 1 to 6 carbon atoms, 10 to 30 g of pulverized natural product, reflux time of 1 to 3 hours, and 50 to 100% of alcohol or water with 1 to 6 carbon atoms. More specifically, based on 100 mL of alcohol with 1 to 6 carbon atoms or 100 mL of water, 10 to 20 g of pulverized natural product, reflux time of 1 to 2 hours, and 70 to 90% of alcohol or water with 1 to 4 carbon atoms. .

The leaching method is carried out at 15 to 30°C for 24 to 72 hours, and water or 50 to 100% alcohol with 1 to 6 carbon atoms is used as the extraction solvent. More specifically, the extraction is performed at 20 to 25°C for 30 to 54 hours, and the extraction solvent is water or 70 to 80% alcohol with 1 to 6 carbon atoms.

The ultrasonic extraction method proceeds at 30 to 50°C for 0.5 to 2.5 hours, and the extraction solvent is water or 50 to 100% alcohol with 1 to 6 carbon atoms. Specifically, extraction is performed at 40 to 50°C for 1 to 2.5 hours, and the extraction solvent is water or 70 to 80% alcohol with 1 to 6 carbon atoms.

The extraction solvent can be used in an amount of 2 to 50 times, more specifically, 2 to 20 times the weight of the sample. For extraction, the sample may be left in the extraction solvent for 1 to 72 hours, more specifically, 24 to 48 hours.

After extraction, the extract can be fractionated by sequentially applying a new fractionation solvent. The fractionating solvent used during fractionation is at least one selected from the group consisting of water, hexane, butanol, ethyl acetic acid, ethyl acetate, methylene chloride, and mixtures thereof, and is preferably ethyl acetate or methylene chloride. After obtaining the extract or fraction, additional methods such as concentration or freeze-drying can be used.

The muscle diseases include atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, amyotrophic lateral sclerosis, Charcot- It is characterized by at least one selected from the group consisting of Charcot-Marie-Tooth disease and sarcopenia.

The above-mentioned dystrophy refers to a condition in which muscle tone is reduced or lost. Muscle tension is controlled centrally and reflexively, and depending on the disorder of this control mechanism, muscle tension can increase, decrease, or disappear. This term is also used when the muscles of the autonomic nervous system (heart, stomach, intestines) experience a decrease or loss of tension.

Muscular dystrophy is a condition in which the muscles of the extremities gradually atrophy almost symmetrically, and there are several forms. The most common ones are amyotrophic lateral sclerosis and spinal progressive muscular atrophy. They are all caused by progressive degeneration of motor nerve fibers and cells in the spinal cord, but the cause is unknown. Amyotrophic lateral sclerosis is an incurable disease whose cause is still unknown since it was first reported in Europe in the late 19th century. It is well known that British astronomer Stephen Hawking suffered from this disease, and it is also called ‘Lou Gehrig’s disease’ because American Major Leaguer L. Gehrig died from this disease.

Muscular dystrophy is characterized by degeneration of skeletal muscles that is not related to the central nervous system and peripheral nervous system, resulting in muscle weakness, contracture, and deformation. Muscle dystrophy or progressive symmetrical muscle atrophy occurs in specific muscles. Muscular dystrophy is characterized by the degree of muscle weakness and genetic factors. It is classified into several types depending on the pattern.

Muscular dystrophy is sometimes used interchangeably with muscular dystrophy, but there are some differences in clinical symptoms. Muscular dystrophy mainly occurs in childhood, and muscular dystrophy occurs in adolescence. Additionally, muscular dystrophy occurs in the proximal muscles, and muscular dystrophy occurs in the distal muscles. Muscle stiffness is not present in muscular dystrophy but is present in muscular dystrophy. Muscular dystrophy is definitely hereditary, but muscular atrophy rarely has a genetic tendency.

The composition exhibits the ability to inhibit differentiation of osteoclasts.

Muscle loss and osteoclasts, which cause sarcopenia or osteoporosis, are cells that destroy bone tissue, and healthy bones can be maintained only when they are in good balance with osteoblasts, cells that create bone tissue.

Therefore, the composition for preventing and treating muscle diseases of the present invention can effectively inhibit the differentiation of osteoclasts, achieve a balance with osteoblasts, and prevent or treat diseases or disorders caused by excessive differentiation of osteoclasts. there is.

The composition increases muscle mass through the effect of promoting muscle fiber formation.

As muscle growth is due to the formation of different muscle fibers through the combination between individual myoblasts, the composition for preventing and treating muscle diseases of the present invention increases muscle mass through the effect of promoting muscle fiber formation, thereby indicating muscle growth. .

Preferably, the composition for preventing and treating muscle diseases of the present invention is selected from the group consisting of Viburnum erosum Thunb. extract, Cryptotaenia japonica extract, Lilium amabile extract, and mixtures thereof. Natural extracts may additionally be included.

The Viburnum erosum Thunb. is a deciduous broad-leaved shrub belonging to the genus of L. vulgaris and is commonly found in low mountain areas south of Gyeonggi-do. It is a short tree of the honeysuckle family, reaching a height of 2 to 3 m. Its white flowers in spring and red fruits in fall are beautiful, so it is often planted as a park tree. The leaves are oval in shape and grow opposite to each other. The fur on the front and back is thick, giving it a soft feel when touched. The stem is characterized by splitting into several pieces and growing in bundles, and the flowers bloom in April to May with white bisexual flowers forming a round shape at the ends of new branches. The small red bean-like fruits ripen red in September or October and are good food for birds. It grows in forests with moderate sunlight and likes soil with good moisture retention and drainage. It has very strong cold resistance, grows well in both sunny and shaded areas, and has the characteristic of growing well even in dry environments. Meanwhile, the name Lesser Pheasant Tree appears to be related to pheasants. Specifically, it is presumed that it was called a wild pheasant tree, meaning that it has fruits that pheasants in the field like, and then became a lesser pheasant tree. The young leaves can be eaten as a vegetable, and the old leaves and stems are used as a medicine for stomatitis or itching in oriental medicine.

Cryptotaenia japonica is an herb that grows in mountainous areas in Korea, also known as fireweed. The height is about 30 to 60 cm. The stem is erect, slightly split, hairless, and fragrant. The stem and leaves are green and the roots are thick. The leaves are alternate, have long petioles of 5 to 17 cm, and consist of three small leaves, which are characterized by a glossy appearance on the back. Meanwhile, the small leaf at the end has no petiole and is egg-shaped, 3 to 8 cm long and 2 to 6 cm wide. The end is sharp, the bottom narrows sharply, and there are sharp, irregular teeth at the edge. The small leaves on the sides are the same size and shape, have no petioles, and sometimes have irregular sawtooth edges that are shallowly divided into 2 or 3 pieces. The flowers are white or light purple and grow in compound umbels at the ends of branches from June to July. There are 1 to 4 small peduncles, either long or short, measuring 3 to 15 mm in length and standing upright. The small gun pieces are string-shaped and short. There are 5 petals, the ends of which are curved inward, 5 sepals, and 5 stamens. The fruit is a meristematic fruit that is 3 to 4 mm long, oval in shape, has no hairs, and ripens in August to September. Young leaves are edible and grown as a vegetable. Those collected in the summer are dried in the shade and used as medicine for goiter, etc.

The above-mentioned Lilium amabile is a perennial herb of the monocotyledonous plant Liliaceae family and is commonly grown in mountainous regions of Korea. It grows up to 50 to 100 cm in height, the stem is erect, the upper part is slightly split, and gray fine hairs grow all over. The scales are 2 to 4 cm long, 15 to 25 mm in diameter, and have an egg-shaped oval shape. The leaves are alternate, line-shaped or lanceolate, 3 to 7 cm long and 3 to 8 mm wide. It is dull green, has blunt or pointed ends, and has dense fine hairs on both sides. The edges are plain, there are no petioles, and the size becomes smaller toward the top. Meanwhile, flowers bloom from June to August, and 1 to 5 flowers hang downward at the ends of branches and main stems. The perianth pieces are lanceolate in number, 4 to 7 cm long, and 10 to 15 mm wide. It is turned backwards and has black or purple spots on the inside. All six stamens and one pistil extend long out of the flower. The anthers are yellowish-red and are about 10 to 13 mm long. The fruit is a capsule that is broadly oval and egg-shaped and ripens in September to October. It is planted for ornamental purposes, and its scaly stems in early spring are edible, and along with lily lily, it is also used as a medicine.

When the natural extract is additionally included in the composition of the present invention, the stability of the composition can be maximized due to the synergistic effect of mixing it with the Brachypodium herb extract, and the effect of inhibiting osteoclast differentiation and promoting muscle fiber formation can be maximized.

Furthermore, when using the composition as a health functional food, etc., there is an advantage in that the preference can also be maximized.

More preferably, the composition for preventing or treating muscle disease of the present invention is composed of 10 to 20 parts by weight of Eucalyptus chinensis extract, 10 to 20 parts by weight of Paddeuk sprouts extract, and 10 to 20 parts by weight of Lilium lily lily extract, based on 100 parts by weight of the Euphorbia chinensis extract. It may include weight parts.

In the case of the above weight range, not only can the osteoclast differentiation inhibitory effect and muscle fiber formation promoting effect be maximized, but also the preference can be maximized.

A pharmaceutical composition according to another embodiment of the present invention is prepared including the composition.

The pharmaceutical composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterilized injection solutions according to conventional methods.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose ( It can be prepared by mixing sucrose, lactose, gelatin, etc.

Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. .

Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.

As a base for suppositories, witepsol, macrogol, tween 61, cacao, laurin, glycerogeratin, etc. can be used.

The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, and hydrogen phosphate. Calcium, lactose, mannitol, taffy, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, Calcium stearate, white sugar, dextrose, sorbitol, and talc may be used.

Additionally, the dosage of the pharmaceutical composition according to the present invention may be increased or decreased depending on the route of administration, severity of disease, gender, weight, age, etc. Accordingly, the above dosage does not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount, and the term "pharmaceutically effective amount" in the present invention refers to the amount used to treat or prevent a disease with a reasonable benefit/risk ratio applicable to medical treatment or prevention. It refers to a sufficient amount, and the effective dose level is determined by the severity of the disease, the activity of the drug, the patient's age, weight, health, gender, the patient's sensitivity to the drug, the administration time, route of administration, and excretion rate of the composition of the present invention used. Factors including the duration of time, drugs used in combination or concurrently with the compositions of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention can be administered alone or in combination with a known immunotherapeutic agent. It is important to consider all of the above factors and administer the amount that will achieve the maximum effect with the minimum amount without side effects.

A food composition according to another embodiment of the present invention is manufactured including the above composition.

The food composition according to the present invention may be provided in the form of powder, granules, tablets, capsules, syrup or beverage, and may be used with other foods or food additives, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on its purpose of use, such as prevention, health, or therapeutic treatment.

As a specific example, the above food composition can be used to produce processed food that can enhance the activity of preventing or improving muscle disease. These processed foods include, for example, snacks, beverages, alcoholic beverages, fermented foods, canned foods, processed milk foods, processed meat foods, noodles, etc. Confectionery includes biscuits, pies, cakes, bread, candy, jellies, gum, cereals, etc. Beverages include drinking water, carbonated beverages, functional ionic beverages, functional ionic beverages, juices (e.g., apple, pear, grape, aloe, tangerine, peach, carrot, tomato juice, etc.), Sikhye, etc. Alcoholic beverages include sake, whiskey, soju, beer, liquor, and fruit wine. Fermented foods include soy sauce, soybean paste, and red pepper paste. Canned food includes canned seafood (e.g., canned tuna, mackerel, saury, canned conch, etc.), canned livestock products (canned beef, pork, chicken, turkey, etc.), and canned agricultural products (canned corn, peaches, canned file apple, etc.). Milk processed foods include cheese, butter, yogurt, etc. Processed meat products include pork cutlet, beef cutlet, chicken cutlet, and sausage. Includes sweet and sour pork, nuggets, neobiani, etc. Includes noodles such as raw noodles in sealed packaging. In addition, the composition can be used in retort foods, soups, etc.

When using the food composition of the present invention as a food additive, the food composition may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The active ingredient can be used appropriately depending on its purpose of use (prevention or improvement).

At this time, the amount of the extract in the food or beverage can be added at about 0.01 to 15% by weight of the total weight of the food, and the health drink composition can be added at a rate of about 0.01 to 10g based on 100 ml, but is not limited thereto. .

When the food composition of the present invention is a beverage composition, other than containing the extract as an essential ingredient in the ratio indicated, there are no particular restrictions on other ingredients, and various flavoring agents or natural carbohydrates may be contained as additional ingredients like ordinary beverages. You can. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (thaumatin, stevia extract (e.g. rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used, but are not limited to these. The ratio of the natural carbohydrate may generally range from about 1 to 20 g per 100 ml of the composition of the present invention, but may not be limited thereto.

In addition to the above, the composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its It may contain salt, organic acid, protective colloidal thickener, Ph adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent used in carbonated beverages, etc., but may not be limited thereto.

In addition, the composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks, and these ingredients can be used independently or in combination. The proportion of these additives is not critical, but may be selected in the range of about 0.1 to about 20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto.

Functional foods as referred to in the present invention include health supplements, which are foods manufactured and processed using specific ingredients as raw materials or specific ingredients contained in food ingredients by methods such as extraction, concentration, purification, and mixing for the purpose of health supplementation, In addition, it is a food designed and processed to fully exert the bioregulatory functions of food ingredients, such as biodefense, regulation of biorhythm, prevention and recovery of disease, etc., and also has functions related to disease prevention and recovery from disease. Make sure to include everything.

There are no particular restrictions on the types of health functional foods. The food composition of the present invention can be manufactured into food, especially functional food. The functional food of the present invention includes ingredients commonly added during food production, and includes, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when manufacturing a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., , xylitol, sorbitol, erythritol, etc.) are preferred. The flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.). In addition to the above health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonic acid. It may further contain carbonating agents used in beverages.

The present invention relates to a composition for the prevention or treatment of muscle disease containing an extract of Brachyphylla sinensis as an active ingredient. In more detail, it has the effect of increasing muscle mass by reducing the differentiation of osteoclasts related to muscle loss and promoting the formation of muscle fibers by including the extract of Achyranthes ginseng as an active ingredient. At the same time, there is no problem of side effects even if the dosage and period of use are increased. It relates to a composition for preventing or treating muscle diseases.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement it. However, the present invention may be implemented in many different forms and is not limited to the embodiments described herein.

[Preparation Example 1: Preparation of natural extract]

1. Preparation of Umbrella extract

The baby radish sprouts were washed, dried, and then pulverized. The ground product was mixed with ethanol, maintained at 98 to 100° C. for 2 hours, cooled, and filtered through Whatman filter paper to obtain the filtrate. This was prepared with Elephant herb extract (ESA).

2. Preparation of other natural extracts

Using the same method as the method for producing the above-mentioned Elephant eucalyptus extract (ESA), EVE extract (EVE), EVE extract (ECJ), and ELA extract were prepared.

3. Preparation of mixed extract

A mixed extract was prepared by mixing the prepared above-mentioned Elephant eucalyptus extract (ESA), Elephant eucalyptus extract (EVE), Elephant eucalyptus extract (ECJ), and Lilium eucalyptus extract (ELA) within the weight range shown in Table 1 below.

M1 M2 M3 M4 M5 ESA 100 100 100 100 100 EVE - 5 10 20 25 ECJ - 5 10 20 25 ELA - 5 10 20 25

(Unit: parts by weight)

[Example 1: Experiment on the effect of promoting muscle fiber formation]

Preparation of myoblasts

Five-week-old male CrljOri:CD1 (ICR) mice were sacrificed and hindlimb muscle tissue was obtained. Muscle tissue was minced with a scalpel for 5 min. The minced muscle solution was incubated at 37°C for 60 minutes and then centrifuged at 1500 rpm for 5 minutes. The obtained cells were plated on cell culture dishes for 1 hour without gelatin coating in Ham's F-10 medium containing 20% heat-inactivated horse serum and 50 units/ml of penicillin in the presence of basic FGF (2.5 ng/ml). . After 1 h, the suspended cells were transferred to a secondary cell culture dish without gelatin coating and incubated for 1 h. This process was repeated and the cells were then transferred to gelatin-coated dishes. Cultured cells were used as myoblasts.

Myoblast differentiation (muscle fiber formation)

Myoblasts obtained from muscle tissue were cultured at 3 x 10 ⁴ per well in a 48-well tissue culture plate pretreated with 10% Matrigel. After culturing for about 24 hours, the growth culture was further cultured in DEM fusion medium containing 5% heat-inactivated horse serum and 50 units/ml of penicillin/streptomycin. The medium was changed once every two days. After culture, cells in 48 wells were washed with PBS (phosphate buffered saline) and fixed using 70% ethanol. Ethanol was removed, and the formed muscle fibers were stained using LADD staining reagent containing Toluidine blue and Fuchsin. After incubation for 1 minute, the stained cells were washed with distilled water until the LADD staining solution was not leached into the water. After washing, the cells were dried at room temperature for 10 minutes.

The myotube stained with the LADD stain was treated with the Aerobium sage extract (ESA, M1) and the mixed extract M2 to M5 prepared in Preparation Example 1 at a concentration of 1mM, and then treated with vehicle as a control. The number of nuclei in the formed myotube was measured.

The results are shown in Table 2 below.

control group
(vehicle processing) M1 M2 M3 M4 M5 Myotube Count 22 33 48 55 58 42

(Unit: index)

As shown in Table 2, the Achyranthesia extract (ESA, M1) and the mixed extracts M2 to M5 of the present invention have a higher number of nuclei in the myotube compared to the number of nuclei in the myotube treated with the vehicle. It was found that the fusion of myoblasts was promoted by increasing , through which it was confirmed that the composition of the present invention exhibits an effect of promoting gold fiber formation.

In particular, it was confirmed that the effect was further improved in the case of M2 to M5, compared to the case containing only the Euphorbiaceae extract (ESA, M1), and the effect was confirmed to be maximized in M4.

[Example 2: Experiment on osteoclast differentiation inhibition effect]

Preparation of bone marrow-derived macrophages (BMM)

Five-week-old male CrljOri:CD1 (ICR) mice were sacrificed, and femurs and tibiae were harvested from the mice. Bone marrow cells were obtained by washing bone marrow from the femur and tibia. Non-adherent bone marrow cells were further cultured with α-MEM and M-CSF (30 ng/ml) for 3 days to generate bone marrow-derived macrophages (BMMs).

Osteoclast differentiation and tartrate-resistant acid phosphatase (TRAP) staining

To generate osteoclasts, the bone marrow-derived macrophages (4 x 10 ⁴ cells/well) were heat-inactivated at 10% (v/v) in the presence of M-CSF (30 ng/ml) and RANKL (100ng/ml). The cells were cultured in a 48-well plate for 4 days with α-MEM complete medium containing fetal bovine serum (FBS) and 50 units/ml of penicillin/streptomycin.

The medium was changed every 3 days. Multinucleated cells (MNC) were observed on day 4. Cells were fixed in 10% formalin solution for 20 minutes and permeabilized with 0.1% Triton X-100 for 1 minute. After washing twice with PBS, cells were stained using Sigma-Aldrich's Leukocyte Acid Phosphatase Assay Kit according to the manufacturer's instructions. The degree of differentiation was evaluated by determining the number of differentiated osteoclasts per well based on osteoclasts with five or more nuclei.

The results are shown in Table 3 below.

control group
(untreated) M1 M2 M3 M4 M5 TRAP positive MNCs per well 300 240 206 198 167 226

(Unit: index)

As shown in Table 3, it was confirmed that the Elephant cerulean extract (ESA, M1) and mixed extracts M2 to M5 of the present invention inhibited the differentiation of bone marrow-derived macrophages into osteoclasts compared to the untreated control group. .

In particular, it was confirmed that the effect was further improved in the case of M2 to M5, compared to the case containing only the Euphorbiaceae extract (ESA, M1), and the effect was confirmed to be maximized in M4.

[Example 3: Evaluation of preference]

In order to evaluate the sensory properties of the Aerobium chinensis extract (ESA, M1) and the mixed extract M2 to M5 of the present invention confirmed in Examples 1 to 2, they were prepared as tea and used on 30 adult men and women in their 20s to 70s. The subjects were asked to evaluate taste, aroma, and overall preference.

The sensory evaluation is requested with an index of 1 to 10, and the higher the score, the better the preference. Meanwhile, for relative comparison, the index of T1 was set to 3.

The results are shown in Table 4 below.

M1 M2 M3 M4 M5 taste 5 6 7 8 7 incense 5 7 8 9 6 Comprehensive preference 5.0 6.5 7.5 8.5 6.5

(Unit: index)

As shown in Table 4, it can be seen that the evaluation of taste and aroma is superior in the case of the mixed compositions M2 to M5 compared to the case containing only the Euphorbiaceae extract (ESA, M1).

In particular, in the case of M3 to M4, the preference was evaluated as excellent, and it can be seen that the preference evaluation of M4 was the best.

That is, in the case of the mixed composition in the above range, it can be confirmed that not only the effect of preventing or treating muscle disease is maximized, but also the preference is maximized when used in health functional foods.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims are also possible. falls within the scope of rights.

Claims (7)

It is a composition for preventing or treating muscle diseases containing Syneilesis aconitifolia (Bunge) Maxim extract as an active ingredient,
The muscle diseases include atony, muscular atrophy, muscular dystrophy, myasthenia gravis, cachexia, rigid spine syndrome, amyotrophic lateral sclerosis, Charcot- Characterized by at least one selected from the group consisting of Charcot-Marie-Tooth disease and sarcopenia
Composition for preventing or treating muscle diseases. According to paragraph 1,
The extract is extracted using an extraction solvent selected from the group consisting of water, C ₁ to C ₆ lower alcohols, and mixtures thereof.
Composition for preventing or treating muscle diseases. delete According to paragraph 1,
The composition exhibits the ability to inhibit differentiation of osteoclasts.
Composition for preventing or treating muscle diseases. According to paragraph 1,
The composition increases muscle mass through the effect of promoting muscle fiber formation.
Composition for preventing or treating muscle diseases. Comprising a composition for treating muscle disease according to any one of claims 1, 2, 4, and 5.
Pharmaceutical composition. Containing a composition for preventing muscle disease according to any one of paragraphs 1, 2, 4, and 5.
Food composition.